A Trial of Lopinavir-Ritonavir in Covid-19.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed.

1. DFV890: a new oral NLRP3 inhibitor-tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function.Infection · 2023
   Trial
2. An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines.Heliyon · 2023
   Review
3. Repurposed pharmacological agents for the potential treatment of COVID-19: a literature review.Respiratory research · 2021
   Review
4. Post-exposure prophylaxis against SARS-CoV-2 in close contacts of confirmed COVID-19 cases (CORIPREV): study protocol for a cluster-randomized trial.Trials · 2021
   Article
5. Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients.European journal of clinical pharmacology · 2021
   Article
6. Structural and molecular basis of the interaction mechanism of selected drugs towards multiple targets of SARS-CoV-2 by molecular docking and dynamic simulation studies- deciphering the scope of repurposed drugs.Computers in biology and medicine · 2020
   Article
7. Update on Antiviral Strategies Against COVID-19: Unmet Needs and Prospects.Frontiers in immunology · 2020
   Review
8. COVID-19: High-JAKing of the Inflammatory "Flight" by Ruxolitinib to Avoid the Cytokine Storm.Frontiers in oncology · 2020
   Article
9. Understanding Severe Acute Respiratory Syndrome Coronavirus 2 Replication to Design Efficient Drug Combination Therapies.Intervirology · 2020
   Review

Corrections and comments

• Commented on by
  A Trial of Lopinavir-Ritonavir in Covid-19. Reply.2020
• Comment on
  A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.2020

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as